S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How does the Consumer Price Index affect the stock market?
3 reasons to buy AMD before 2024
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Generative AI boosts UiPath; analysts see triple-digit EPS growth
All the trading advice you’ve ever received boils down to this (Ad)
3 must-own China stocks for the Year of the Dragon
Broadcom falls into a buy-the-dip opportunity 

Acasti Pharma Stock Price, News & Analysis (NASDAQ:ACST)

$2.30
-0.03 (-1.29%)
(As of 12/8/2023 ET)
Compare
Today's Range
$2.22
$2.34
50-Day Range
$2.05
$2.82
52-Week Range
$1.72
$5.05
Volume
7,441 shs
Average Volume
28,176 shs
Market Capitalization
$21.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.70

Acasti Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
539.1% Upside
$14.70 Price Target
Short Interest
Healthy
1.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$1.25 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.44) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

116th out of 954 stocks

Pharmaceutical Preparations Industry

27th out of 362 stocks


ACST stock logo

About Acasti Pharma Stock (NASDAQ:ACST)

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Price History

ACST Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Acasti announces $7.5M private placement equity funding
Acasti Pharma: Reverse Stock Split To Become Effective July 10
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Acasti Pharma Announces 1-for-6 Reverse Stock Split
Recap: Acasti Pharma Q4 Earnings
Acasti Pharma's Earnings Outlook
H.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)
See More Headlines
Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/08/2023
Next Earnings (Estimated)
2/13/2024
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.70
High Stock Price Target
$15.00
Low Stock Price Target
$14.40
Potential Upside/Downside
+539.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$200,000.00
Book Value
$9.14 per share

Miscellaneous

Free Float
8,129,000
Market Cap
$21.62 million
Optionable
Not Optionable
Beta
1.27
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Prashant Kohli (Age 51)
    CEO & Director
    Comp: $358.41k
  • Mr. Brian D. Ford CPA (Age 64)
    CA, Interim Chief Financial Officer
    Comp: $379.35k
  • Dr. R. Loch MacDonald M.D. (Age 61)
    Ph.D., Member of Scientific Advisory Board & Chief Medical Officer
  • Mr. Amresh Kumar Ph.D. (Age 43)
    VP of Program Management
  • Ms. Carrie D'Andrea (Age 51)
    VP of Clinical Operations














ACST Stock Analysis - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings
or view top-rated stocks.

What is Acasti Pharma's stock price target for 2024?

2 brokers have issued 12-month price objectives for Acasti Pharma's shares. Their ACST share price targets range from $14.40 to $15.00. On average, they predict the company's stock price to reach $14.70 in the next twelve months. This suggests a possible upside of 539.1% from the stock's current price.
View analysts price targets for ACST
or view top-rated stocks among Wall Street analysts.

How have ACST shares performed in 2023?

Acasti Pharma's stock was trading at $3.0060 at the beginning of 2023. Since then, ACST stock has decreased by 23.5% and is now trading at $2.30.
View the best growth stocks for 2023 here
.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 91,900 shares, a decline of 10.0% from the October 31st total of 102,100 shares. Based on an average daily trading volume, of 49,200 shares, the short-interest ratio is presently 1.9 days. Currently, 1.5% of the shares of the stock are short sold.
View Acasti Pharma's Short Interest
.

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ACST earnings forecast
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) issued its earnings results on Monday, November, 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.10.

When did Acasti Pharma's stock split?

Shares of Acasti Pharma reverse split on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACST) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -